February 2022 Editor’s Choice: HRD: What does it really mean and are we looking at this the right way?
Listen to Gynecologic Oncology
English - February 03, 2022 05:15Science Health & Fitness medicine health care science and technology health national health service medical disease cancer politics diabetes Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: January 2022 Editor’s Choice: Optimizing Rural Ovarian Cancer Care
Hosted by:
Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic Oncology
Featuring:
Elizabeth Swisher, MD, UW Medicine
Jonathan A Ledermann, MD FRCP FMedSci Professor of Medical Oncology, UCL Cancer Institute
Editor’s Choice Paper: Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study
Editorial: Testing for homologous recombination deficiency – does it provide new insights for the use of veliparib?